Invention Grant
US08173650B2 Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
有权
双环嘧啶PI3K抑制剂化合物选择性为P110δ，以及使用方法
- Patent Title: Bicyclic pyrimidine PI3K inhibitor compounds selective for P110 delta, and methods of use
- Patent Title (中): 双环嘧啶PI3K抑制剂化合物选择性为P110δ，以及使用方法
-
Application No.: US12787613Application Date: 2010-05-26
-
Publication No.: US08173650B2Publication Date: 2012-05-08
- Inventor: Georgette Castanedo , Bryan Chan , David Goldstein , Rama Kondru , Matthew Lucas , Wylie Palmer , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Zachary K. Sweeney
- Applicant: Georgette Castanedo , Bryan Chan , David Goldstein , Rama Kondru , Matthew Lucas , Wylie Palmer , Stephen Price , Brian Safina , Pascal Pierre Alexandre Savy , Eileen Mary Seward , Daniel P. Sutherlin , Zachary K. Sweeney
- Applicant Address: US CA South San Francisco
- Assignee: Genentech, Inc.
- Current Assignee: Genentech, Inc.
- Current Assignee Address: US CA South San Francisco
- Agent Alex Andrus
- Main IPC: A61K31/535
- IPC: A61K31/535 ; C07D413/14
Abstract:
Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, or (iv) X1 is CR7 and X2 is O, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Public/Granted literature
- US20100305096A1 BICYCLIC PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE Public/Granted day:2010-12-02
Information query
